林业发展局批准了第一个AI工具AIM-NASH, 使MASH临床试验中的肝脏活性检查分析标准化,提高效率和一致性。 The FDA has approved the first AI tool, AIM-NASH, to standardize liver biopsy analysis in MASH clinical trials, boosting efficiency and consistency.

林业发展局对第一个AI工具AIM-NASH进行了资格认证,以协助临床试验新陈代谢机能失调 -- -- 一种严重的脂肪性肝病 -- -- 相关肝炎(MASH)。 The FDA has qualified the first AI tool, AIM-NASH, to assist in clinical trials for metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. 基于云的系统分析肝脏生物切片图像,以便对脂肪、炎症和疤痕进行标准化评估,提高试验数据收集的一致性和效率。 The cloud-based system analyzes liver biopsy images to provide standardized assessments of fat, inflammation, and scarring, improving consistency and efficiency in trial data collection. 虽然最终诊断仍由人类病理学家进行,但该工具旨在减少变异性并加速药物开发,从而可能减少试用时限和费用。 While final diagnoses remain with human pathologists, the tool aims to reduce variability and accelerate drug development, potentially cutting trial timelines and costs. 它现在可以在任何药物发展方案中,在合格的使用范围内使用。 It is now available for use in any drug development program under the qualified context of use.